Work

The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.

Year: 2007

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v110.11.3536.3536

Authors: Jason Gotlib, Tracy I. George, Chris Corless, Andrea Linder, Alisa Ruddell, Cem Akin, Daniel J. DeAngelo, Ilana Kepten, Carlo Lanza, Heidrun Heinemann, Ophelia Yin, Neil Gallagher, Tim Graubert

Institutions: Stanford Medicine, Stanford University, Oregon Health & Science University, Washington University in St. Louis, University of Michigan, Dana-Farber Cancer Institute, Novartis (Switzerland)

Language: English

Topic: Mast cells and histamine

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2557604960

FWCI: 1.232

Cites:

Cited by: 21

Related to: 10